Desensitization of highly pre-sensitized dialysis patients waiting for kidney transplantation by rituximab, intravenous immunoglobulin-L (IVIG-L) and rescue plasmapheresis (AMC-DRIP)
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2013
At a glance
- Drugs Immune globulin (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms DRIP
- 29 Jun 2013 Status changed from planning to completed as reported by ISRCTN: Current Controlled Trials.
- 25 Jun 2007 New trial record.